Thera-SAbDab

SERIBANTUMAB

>   Structural Summary
TherapeuticSeribantumab
TargetERBB3
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAASGFTFSHYVMAWVRQAPGKGLEWVSSISSSGGWTLYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTRGLKMATIFDYWGQGTLVTVSS
Light ChainQSALTQPASVSGSPGQSITISCTGTSSDVGSYNVVSWYQQHPGKAPKLIIYEVSQRPSGVSNRFSGSKSGNTASLTISGLQTEDEADYYCCSYAGSSIFVIFGGGTKVTVL
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG2
Highest Clinical Trial (June '19)Phase-II
Estimated Status (June '19)Discontinued
Recorded Developmental TechnologyDyax Human Phage Display
INN Year Proposed2012
INN Year Recommended2013
Companies InvolvedMerrimack Pharmaceuticals, Sanofi
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBreast cancer, Gynaecological cancer, Non-small cell lung cancer, Ovarian cancer, Solid tumours
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]